Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RT001
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Revio Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Peptris Technologies out-licenses AI-discovered drug candidate to Revio Therapeutics
Details : Under the licensing agreement, Revio will hold commercialisation rights to PEPR124 (RT001) in all markets except in BRICS countries, which will be retained by Peptris.
Product Name : PEPR124
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 17, 2025
Lead Product(s) : RT001
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Revio Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement